Terapias biológicas en el lupus eritematoso sistémico
-
-
[1] Universidad de la República
Universidad de la República
Uruguay
-
[2] Hospital Clínic Institut Clínic de Medicina y Dermatologia Servicio de Enfermedades Autoinmunes
-
- Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 138, Nº. 7, 2010, págs. 881-887
- Idioma: español
- Títulos paralelos:
- Biological therapies in systemic lupus erythematosus
- Enlaces
-
Resumen
The immunosuppressive agents used in patients with systemic lupus erythematosus (SLE) have signifcantly improved prognosis. However, it is necessary to develop more specifc immunosuppressive treatments with less toxicity. Better understanding of the mechanisms involved in the loss of tolerance in autoimmune diseases has contributed to the development of potential new treatments called biologic therapies. The targets of these biological therapies are directed toward the B cell depletion, interference in the co-stimulation signals and the blockade of cytokines. Therapies using anti-CD20 monoclonal antibodies have shown satisfactory results especially in patients with SLE refractory to conventional treatment. The biological therapies provide encouraging results that represent a possible option in the treatment of refractory patients as well as a potential therapy in the future management of SLE.
